Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

NCT01808599 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

112

Enrollment

OTHER

Sponsor class

Conditions

MALT Lymphoma

Interventions

DRUG: Chlorambucil
DRUG: Rituximab i.v.
DRUG: Rituximab s.c.

Sponsor

International Extranodal Lymphoma Study Group (IELSG)